|
1
|
Cheville JC, Lohse CM, Zincke H, Weaver AL
and Blute ML: Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma. Am J Surg Pathol.
27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weiss RH and Lin PY: Kidney cancer:
Identification of novel targets for therapy. Kidney Int.
69:224–232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonassi S and Neri M: Genetic biomarkers
in human population studies. Handbook of Genomic Medicine. Willard
HF and Ginsburg GS: Elsevier; 2008
|
|
4
|
Beck SD, Patel MI, Snyder ME, Kattan MW,
Motzer RJ, Reuter VE and Russo P: Effect of papillary and
chromophobe cell type on disease-free survival after nephrectomy
for renal cell carcinoma. Ann Surg Oncol. 11:71–77. 2004.
View Article : Google Scholar
|
|
5
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
6
|
Matsumoto S, Hyodo F, Subramanian S,
Devasahayam N, Munasinghe J, Hyodo E, Gadisetti C, Cook JA,
Mitchell JB and Krishna MC: Low-field paramagnetic resonance
imaging of tumor oxygenation and glycolytic activity in mice. J
Clin Invest. 118:1965–1973. 2008.PubMed/NCBI
|
|
7
|
Vaupel P: Metabolic microenvironment of
tumor cells: A key factor in malignant progression. Exp Oncol.
32:125–127. 2010.
|
|
8
|
Wenger RH, Stiehl DP and Camenisch G:
Integration of oxygen signaling at the consensus HRE. Sci STKE.
2005:re122005.PubMed/NCBI
|
|
9
|
Trayhurn P, Wang B and Wood IS: Hypoxia
and the endocrine and signalling role of white adipose tissue. Arch
Physiol Biochem. 114:267–276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gnarra JR, Glenn GM, Latif F, Anglard P,
Lerman MI, Zbar B and Linehan WM: Molecular genetic studies of
sporadic and familial renal cell carcinoma. Urol Clin North Am.
20:207–216. 1993.PubMed/NCBI
|
|
11
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in Von
Hippel-Lindau disease-associated and sporadic clear cell carcinoma
of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baldewijns MM, van Vlodrop IJ, Vermeulen
PB, Soetekouw PM, van Engeland M and de Bruïne AP: VHL and HIF
signalling in renal cell carcinogenesis. J Pathol. 221:125–138.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pinthus JH, Whelan KF, Gallino D, Lu JP
and Rothschild N: Metabolic features of clear-cell renal cell
carcinoma: Mechanisms and clinical implications. Can Urol Assoc J.
5:274–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wykoff CC, Beasley NJ, Watson PH, Turner
KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell
PH, et al: Hypoxia-inducible expression of tumor-associated
carbonic anhydrases. Cancer Res. 60:7075–7083. 2000.
|
|
15
|
Bui MH, Seligson D, Han KR, Pantuck AJ,
Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, et
al: Carbonic anhydrase IX is an independent predictor of survival
in advanced renal clear cell carcinoma: Implications for prognosis
and therapy. Clin Cancer Res. 9:802–811. 2003.PubMed/NCBI
|
|
16
|
Takacova M, Bartosova M, Skvarkova L,
Zatovicova M, Vidlickova I, Csaderova L, Barathova M, Breza J Jr,
Bujdak P, Pastorek J, et al: Carbonic anhydrase IX is a clinically
significant tissue and serum biomarker associated with renal cell
carcinoma. Oncol Lett. 5:191–197. 2013.
|
|
17
|
Sedlakova O, Svastova E, Takacova M,
Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX, a
hypoxia-induced catalytic component of the pH regulating machinery
in tumors. Front Physiol. 4:4002014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ditte P, Dequiedt F, Svastova E, Hulikova
A, Ohradanova-Repic A, Zatovicova M, Csaderova L, Kopacek J,
Supuran CT, Pastorekova S, et al: Phosphorylation of carbonic
anhydrase IX controls its ability to mediate extracellular
acidification in hypoxic tumors. Cancer Res. 71:7558–7567. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Svastova E, Witarski W, Csaderova L, Kosik
I, Skvarkova L, Hulikova A, Zatovicova M, Barathova M, Kopacek J,
Pastorek J, et al: Carbonic anhydrase IX interacts with bicarbonate
transporters in lamellipodia and increases cell migration via its
catalytic domain. J Biol Chem. 287:3392–3402. 2012. View Article : Google Scholar :
|
|
20
|
Gorbatenko A, Olesen CW, Boedtkjer E and
Pedersen SF: Regulation and roles of bicarbonate transporters in
cancer. Front Physiol. 16–April;2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karumanchi SA, Jiang L, Knebelmann B,
Stuart-Tilley AK, Alper SL and Sukhatme VP: VHL tumor suppressor
regulates Cl−/HCO3− exchange and
Na+/H+ exchange activities in renal carcinoma
cells. Physiol Genomics. 5:119–128. 2001.PubMed/NCBI
|
|
22
|
Halestrap AP: The SLC16 gene family:
structure, role and regulation in health and disease. Mol Aspects
Med. 34:337–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Doyen J, Trastour C, Ettore F, Peyrottes
I, Toussant N, Gal J, Ilc K, Roux D, Parks SK, Ferrero JM, et al:
Expression of the hypoxia-inducible monocarboxylate transporter
MCT4 is increased in triple negative breast cancer and correlates
independently with clinical outcome. Biochem Biophys Res Commun.
451:54–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pértega-Gomes N, Vizcaíno JR, Attig J,
Jurmeister S, Lopes C and Baltazar F: A lactate shuttle system
between tumour and stromal cells is associated with poor prognosis
in prostate cancer. BMC Cancer. 14:3522014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jóźwiak P, Krześlak A, Pomorski L and
Lipińska A: Expression of hypoxia-related glucose transporters
GLUT1 and GLUT3 in benign, malignant and non-neoplastic thyroid
lesions. Mol Med Rep. 6:601–606. 2012.
|
|
26
|
Brown RS, Goodman TM, Zasadny KR, Greenson
JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated
human breast cancer. Nucl Med Biol. 29:443–453. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mori Y, Tsukinoki K, Yasuda M, Miyazawa M,
Kaneko A and Watanabe Y: Glucose transporter type 1 expression are
associated with poor prognosis in patients with salivary gland
tumors. Oral Oncol. 43:563–569. 2007. View Article : Google Scholar
|
|
28
|
Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim
Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, et al:
Brain tumor initiating cells adapt to restricted nutrition through
preferential glucose uptake. Nat Neurosci. 16:1373–1382. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu JW, Sun P, Zhang DX, Xiong WJ and Mi J:
Hexokinase 2 regulates G1/S checkpoint through CDK2 in
cancer-associated fibroblasts. Cell Signal. 26:2210–2216. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feliciano A, Castellvi J, Artero-Castro A,
Leal JA, Romagosa C, Hernández-Losa J, Peg V, Fabra A, Vidal F,
Kondoh HC, et al: miR-125b acts as a tumor suppressor in breast
tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and
MEGF9. PLoS One. 8:e762472013. View Article : Google Scholar
|
|
31
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suh DH, Kim MA, Kim H, Kim MK, Kim HS,
Chung HH, Kim YB and Song YS: Association of overexpression of
hexokinase II with chemoresistance in epithelial ovarian cancer.
Clin Exp Med. 14:345–353. 2014. View Article : Google Scholar
|
|
33
|
Moon JS, Kim HE, Koh E, Park SH, Jin WJ,
Park BW, Park SW and Kim KS: Krüppel-like factor 4 (KLF4) activates
the transcription of the gene for the platelet isoform of
phosphofructokinase (PFKP) in breast cancer. J Biol Chem.
286:23808–23816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li B, Qiu B, Lee DS, Walton ZE, Ochocki
JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I, et al:
Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature. 13:251–255. 2014. View Article : Google Scholar
|
|
35
|
Girgis H, Masui O, White NM, Scorilas A,
Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason
GA, et al: Lactate dehydrogenase A is a potential prognostic marker
in clear cell renal cell carcinoma. Mol Cancer. 13:1012014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie H, Hanai J, Ren JG, Kats L, Burgess K,
Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, et al:
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor
progression in mouse models of lung cancer and impacts
tumor-initiating cells. Cell Metab. 19:795–809. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schell JC and Rutter J: The long and
winding road to the mitochondrial pyruvate carrier. Cancer Metab.
1:62013.PubMed/NCBI
|
|
38
|
Mayr JA, Meierhofer D, Zimmermann F,
Feichtinger R, Kögler C, Ratschek M, Schmeller N, Sperl W and
Kofler B: Loss of complex I due to mitochondrial DNA mutations in
renal oncocytoma. Clin Cancer Res. 14:2270–2275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yusenko MV, Ruppert T and Kovacs G:
Analysis of differentially expressed mitochondrial proteins in
chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel
electrophoresis. Int J Biol Sci. 6:213–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Simonnet H, Alazard N, Pfeiffer K, Gallou
C, Béroud C, Demont J, Bouvier R, Schägger H and Godinot C: Low
mitochondrial respiratory chain content correlates with tumor
aggressiveness in renal cell carcinoma. Carcinogenesis. 23:759–768.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Choueiri TK, Cheng S, Qu AQ, Pastorek J,
Atkins MB and Signoretti S: Carbonic anhydrase IX as a potential
biomarker of efficacy in metastatic clear-cell renal cell carcinoma
patients receiving sorafenib or placebo: Analysis from the
treatment approaches in renal cancer global evaluation trial
(TARGET). Urol Oncol. 31:1788–1793. 2013. View Article : Google Scholar
|
|
42
|
Page T, Hodgkinson AD, Ollerenshaw M,
Hammonds JC and Demaine AG: Glucose transporter polymorphisms are
associated with clear-cell renal carcinoma. Cancer Genet Cytogenet.
163:151–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
White EA, Kenny HA and Lengyel E:
Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev.
79–80:184–192. 2014. View Article : Google Scholar
|
|
44
|
Fu L, Wang G, Shevchuk MM, Nanus DM and
Gudas LJ: Generation of a mouse model of Von Hippel-Lindau kidney
disease leading to renal cancers by expression of a constitutively
active mutant of HIF1α. Cancer Res. 71:6848–6856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Leibovich BC, Sheinin Y, Lohse CM,
Thompson RH, Cheville JC, Zavada J and Kwon ED: Carbonic anhydrase
IX is not an independent predictor of outcome for patients with
clear cell renal cell carcinoma. J Clin Oncol. 25:4757–4764. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang BY, Thompson RH, Lohse CM, Dronca
RS, Cheville JC, Kwon ED and Leibovich BC: Carbonic anhydrase IX
(CAIX) is not an independent predictor of outcome in patients with
clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
BJU Int. 111:1046–1053. 2013. View Article : Google Scholar : PubMed/NCBI
|
